Divi's Laboratories Ltd (BOM:532488) (Q1 FY27) Earnings Call Highlights: Record Profit Surge ...

Q & A Highlights

Q: Can you provide more details on the significant uptick in the custom synthesis (CS) business, specifically regarding the contribution from the dedicated CapEx projects and the expected ramp-up in quantities? A: Dr. Kiran Divi, CEO, stated that while it is difficult to define the exact contribution, the company is undergoing validation for some CapEx projects, and a certain amount of product has already been shipped to customers. He noted that once validations are complete, customers must conduct their own qualifications and obtain regulatory approvals before commercial quantities begin. He declined to provide specific quantity ranges due to confidentiality agreements (CDAs), emphasizing that product demand varies widely, from 1,000 kgs to 5,000-6,000 tonnes annually.

Q: What is the company's competitive positioning in the global peptide CDMO landscape, given its backward integration and new capacities? A: Dr. Kiran Divi highlighted that Divi's is uniquely positioned as it starts from basic raw materials, manufactures its own peptide building blocks, protected amino acids, and fragments, creating a complete backward integration chain. He stated this provides a significant competitive advantage in cost and supply reliability. He noted "amazing opportunities" in the fragment segment, with several projects in clinical phases or undergoing validations, prompting further capacity expansion with additional 3,000-liter SPPS reactors.

Q: What are the key milestones for the three major CapEx projects before commercial supply begins, and will regulatory approvals be required? A: Dr. Kiran Divi explained that the projects are part of innovator CMC filings and will definitely require regulatory clearances. He stated the company is "completely ready for all regulatory submissions" and prepared for inspections. The timeline for commercialization depends on the customer's filing process and subsequent agency approvals, after which they will have more clarity.

Q: Can you provide qualitative guidance on the margin trajectory for the current financial year, given the challenging raw material environment and currency tailwinds? A: Ms. Nilima Motaparti, Whole-Time Director (Commercial), advised against looking at margins on a quarterly basis due to lumpiness in the business mix. She noted that Q1 FY27 had a higher CS contribution (60%), which typically yields higher margins, but raw material costs, particularly solvents, remain elevated. She reiterated the company's focus on achieving double-digit revenue growth and suggested that full-year EBITDA margins would be similar to the previous year, with gross margins around 60%.

Q: Can you provide an update on the new generic products added to the portfolio and the expected timeline for commercial volumes? A: Dr. Kiran Divi stated that the company has filed about four DMFs in the last few years. Validation quantities have been supplied to customers who are undergoing qualifications. One customer is negotiating a long-term exclusivity agreement. He mentioned specific products like (inaudible) where multiple customers are qualifying, and commercial volumes are expected to move out within the next 3 to 6 months.

Q: What has led to the substantial increase in inventory (change in inventory of ~INR500 crore) this quarter, and will this trend continue? A: Ms. Nilima Motaparti explained that the increase is due to two factors: 1) A conscious decision to maintain a rolling 3-month inventory buffer for critical raw materials to prevent production stoppages and shipment delays, especially given the geopolitical situation in West Asia. 2) Materials procured for the validation batches of new CapEx projects. She confirmed this stocking strategy will continue as long as macro uncertainty persists.

Q: What is the current role of Unit-III (Kakinada) in the supply chain, and what is the overall capacity utilization across the plants? A: Dr. Kiran Divi stated that Unit-III is currently playing a key role in backward integration by taking on pre-chemistry work to free up capacity in the regulatory-approved Unit-I and Unit-II. The long-term plan is to qualify Unit-III with all regulatory clearances, but this process takes time. In the interim, it is being utilized for pre-chemistry products. Ms. Nilima Motaparti added that overall utilization across all three units is around 80-85%.

Q: Are you seeing signs of a positive inflection in generic API pricing, and is this a market correction or a structural change? A: Dr. Kiran Divi clarified that the recent price increases in the generic market are primarily a direct pass-on of substantially higher raw material costs, particularly solvents, which have doubled or tripled in price due to the Middle East situation. He stated this is a "market correction based on raw material prices" rather than an end to the long-term pricing pressure cycle. He confirmed Divi's has also increased prices slightly where necessary to maintain product viability.

Q: Given the strong Q1 performance, how should we model the revenue mix and growth for the remainder of FY27? A: Dr. Kiran Divi reiterated the company's commitment to achieving double-digit revenue growth for the full year. He noted that the future mix between CS and generics depends on the speed of regulatory approvals for the validated projects. He stated, "I would like a healthy mix always," but assured that double-digit growth is the target, with updates provided as regulatory milestones are achieved.

Q: What is the status of the contrast media portfolio, specifically iodine and gadolinium-based products? A: Dr. Kiran Divi provided an update: For iodine-based contrast media, the company is in the process of signing long-term, multi-year contracts with two customers. Commercialization has already started for one, and the second will begin in the next few months, with "substantial quantities" expected. For gadolinium, the project remains in the clinical phase (Phase II/III) with the customer, and the company is waiting for the customer to receive regulatory approvals to advance to the next phase.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .